HOME >> BIOLOGY >> NEWS
Mount Sinai School of Medicine and Bionostra Group collaborate to develop avian flu vaccine

The Mount Sinai School of Medicine announced today it will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.

Founded in 2000, Bionostra - - in collaboration with members of the Consejo Superior de Investigaciones Cientficas (CSIC) which is the Spanish High Council of Scientific Research - - has developed a new technology based on virus-like-particles to provide a new generation of vaccines for human and animal health. These novel technology, will offer researchers at Mount Sinai School of Medicine a great jumping off point in the creation of the vaccine.

"We are enthusiastic with this promising collaboration between Bionostra and the Mount Sinai School of Medicine which is renowned for its prestigious scientific research," said Juan Carlos del Castillo Tamayo, CEO of Bionostra. "This is the first step for a revolutionary new generation of vaccines against the influenza virus."


'"/>

Contact: Lucia Lee
lucia.lee@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
29-Mar-2006


Page: 1

Related biology news :

1. Climate change isolates Rocky Mountain butterflies
2. Bernese Mountain Dogs prone to Borrelia burgdorferi infection
3. Bronfman gift to Mount Sinai catalyzes genomics-based medicine
4. NIH establishes Center of Excellence for influenza research at Mount Sinai
5. Mount Sinai School of Medicine licenses avian flu vaccine to Avimex
6. Sensational find: The mini-dinosaurs from the Harz Mountains
7. Brookhaven Lab and Mount Sinai form joint Center for Translational Biomedical Imaging
8. University of Kentucky author captures national attention with Lost Mountain
9. Infectious disease expert warns of spread of Rocky Mountain spotted fever
10. Mount Sinai receives NIH funding for stem cell research
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: